Blakely York
Medical · Athens, GANPI 1861612525
Payments from drug & device makers
Across 146 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$506
- Amgen$360
- AbbVie$267
- Bayer$230
- AstraZeneca$176
- Pfizer$172
- plus $780 from 22 others
What the payments were for
- Food & beverage$2,491100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $506 |
| Amgen | 20 | $360 |
| AbbVie | 18 | $267 |
| Bayer | 13 | $230 |
| AstraZeneca | 8 | $176 |
| Pfizer | 10 | $172 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $121 |
| Astellas Pharma US Inc | 4 | $72 |
| Lilly USA, LLC | 5 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $63 |
| Exact Sciences | 2 | $53 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $36 |
| GSK | 2 | $31 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Eisai Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $23 |
| Johnson & Johnson | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $20 |
| Novartis | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Merck | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
How this compares
$2,491 in reported general payments places this provider in the 70th percentile of 950 medical providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 24 | $28,685 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $11,097 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 52 | $1,438 |
| Rosuvastatin Calcium | 71 | $1,027 |
| Levothyroxine Sodium | 64 | $920 |
| Fluticasone Propionate | 42 | $558 |
| Gabapentin | 33 | $551 |
| Bupropion XlBupropion Hcl | 16 | $486 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 42 | $399 |
| Omeprazole | 30 | $356 |
| Doxycycline Hyclate | 39 | $353 |
| Cefdinir | 18 | $293 |
| Azelastine Hcl | 18 | $285 |
| Montelukast Sodium | 20 | $270 |
| Fluoxetine Hcl | 12 | $263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $506 | $28,68524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 950 medical providers in Georgia.
Other medical in Athens
- Charles DavisAthens$17K
- Anna McFatherAthens$13K
- Tomas ChaoWoodstock$1.9M
- Kimberly OrleckAtlanta$727K
- Audrey GibsonGainesville$302K
- Lisa WeissCanton$283K
- Laura BushFayetteville$146K
- Michael KelleherMarietta$126K
- Juliena GigonMarietta$122K
- Felicia HoffmanRoswell$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.